Malignant hyperthermia is a rare, potentially fatal reaction to certain general anesthesia drugs, driven by a genetic defect in how skeletal muscle handles calcium. A susceptible person can undergo surgery after surgery with no problems, then experience a sudden, runaway metabolic crisis the next time they go under. The death rate from an episode used to be around 70 percent in the 1970s; thanks to better recognition and a specific antidote, it has dropped to roughly 5 percent today.1Lancet. Malignant hyperthermia That improvement is impressive, but it depends entirely on the surgical team knowing what to look for and acting fast.
What Happens Inside the Muscle
The core problem is a calcium leak. Skeletal muscles contract and relax by tightly controlling the release and reuptake of calcium ions inside muscle cells. That process is managed by a channel protein called the ryanodine receptor, encoded by a gene called RYR1. In people susceptible to malignant hyperthermia, mutations in RYR1 produce an altered version of this receptor that responds abnormally to certain chemical triggers.2PubMed. Malignant hyperthermia: excitation-contraction coupling, Ca2+ release channel, and cell Ca2+ regulation defects When one of those triggers is introduced, calcium floods out of its storage compartment and into the muscle cell in an uncontrolled way, and the cell cannot pump it back fast enough.
Research on porcine muscle first pinpointed this mechanism. The ryanodine receptor in susceptible pigs binds its namesake molecule differently and shows altered sensitivity to calcium at one of its regulatory sites.3PubMed. Abnormal sarcoplasmic reticulum ryanodine receptor in malignant hyperthermia In plain terms, the channel’s “off switch” is faulty. Once the channel opens, it stays open longer and dumps far more calcium than it should.
The consequences ripple outward from there. Muscle fibers contract furiously and will not relax. That sustained contraction burns through the cell’s energy supply, generating enormous amounts of heat, carbon dioxide, and acid as byproducts. If the reaction is not stopped, the muscle cells eventually break down, releasing potassium and a protein called myoglobin into the bloodstream, which can damage the kidneys and destabilize the heart.
What Triggers an Episode
Malignant hyperthermia is a pharmacogenetic disorder, meaning it requires both the genetic susceptibility and exposure to a specific drug to set off a crisis. The triggering agents fall into two categories: potent volatile anesthetic gases, such as halothane, sevoflurane, desflurane, isoflurane, and methoxyflurane; and the depolarizing muscle relaxant succinylcholine.4PubMed Central. Malignant hyperthermia These drugs are staples of general anesthesia, which is partly why the condition caught the medical world off guard when it was first described in the 1960s.
What makes this especially tricky is that a susceptible person may have received one of these agents before without incident. Penetrance is incomplete, meaning the mutation does not guarantee a reaction every single time a trigger is present. A person might have two or three uneventful surgeries and then develop a full-blown crisis on the fourth. The gap between how many people carry the genetic susceptibility and how many actually experience a clinical episode is large and still not fully understood.5British Journal of Anaesthesia. Estimating prevalence of malignant hyperthermia susceptibility through population genomics data
In rare cases, stresses beyond the operating room can also provoke a reaction. Vigorous exercise and extreme heat have been reported as triggers in humans, though these non-anesthetic episodes are much less common.6PubMed Central. Malignant hyperthermia
Recognizing the Signs
An episode typically unfolds during or shortly after the start of anesthesia, though delays of an hour or more are possible. The earliest and most reliable warning sign is a rapid, unexplained rise in the amount of carbon dioxide the patient is exhaling. The anesthesia monitors pick this up before anything else becomes obvious. Other early signs include a fast heart rate and muscle rigidity, especially jaw rigidity after succinylcholine is given.7PubMed Central. Management of malignant hyperthermia: diagnosis and treatment
The actual rise in body temperature, which gives the condition its name, is often a later finding. By the time the thermometer reads high, the metabolic runaway has been underway for a while. Other features of a developing crisis include falling oxygen levels, metabolic acidosis, rising potassium levels in the blood, and eventually dark or cola-colored urine from myoglobin released by damaged muscle. The constellation of signs can overlap with other surgical emergencies, which is why anesthesia training emphasizes pattern recognition and rapid response.
Treatment With Dantrolene
The specific antidote is dantrolene sodium, and its introduction is the main reason the fatality rate collapsed from roughly 70 percent to about 5 percent.8Lancet. Malignant hyperthermia Dantrolene works by acting on the ryanodine receptor itself, essentially helping to reclose the calcium channel and stop the flood. The drug’s mechanism is more nuanced than simply blocking the receptor, though. Research has shown that dantrolene actually needs magnesium to be effective. In the absence of magnesium, dantrolene has little impact on calcium release. As magnesium concentrations rise past resting levels, the drug increasingly helps the receptor return to its closed state.9PubMed Central. Dantrolene requires Mg(2+) to arrest malignant hyperthermia During an actual crisis, the cell’s own magnesium levels rise because the energy molecule MgATP is being broken down rapidly, which is thought to help dantrolene do its job in a real clinical setting.
Treatment protocol goes beyond the drug itself. The surgical team simultaneously stops all triggering agents, hyperventilates the patient with pure oxygen, starts active cooling with ice packs and cold intravenous fluids, and monitors for dangerous potassium levels and heart rhythm disturbances. Speed matters enormously. Operating rooms that stock dantrolene and have rehearsed the protocol are far better positioned than those that haven’t. Simulation exercises with emergency checklists have been shown to reduce the number of critical treatment steps that get missed during these high-pressure events.10Elsevier / Journal of PeriAnesthesia Nursing. Malignant Hyperthermia Preparedness Training: Using Cognitive Aids and Emergency Checklists in the Perioperative Setting
Newer formulations of dantrolene have improved its practical handling. The original powder was notoriously difficult and slow to mix, which is a serious limitation when minutes count. A more recently introduced formulation improved the drug’s ability to dissolve in water, making preparation faster.11PubMed Central. Current clinical application of dantrolene sodium.
How Susceptibility Is Diagnosed
Two main approaches exist for confirming whether someone is susceptible: a muscle biopsy test and genetic analysis. The gold standard remains the caffeine-halothane contracture test, in which a small piece of muscle is surgically removed and exposed to caffeine and halothane in a lab. If the muscle contracts more readily than normal, the person is classified as susceptible. The test’s sensitivity can reach around 97 percent, meaning it catches nearly all truly susceptible individuals, with a specificity around 78 percent.12Anesthesiology. The Sensitivity and Specificity of the Caffeine-Halothane Contracture Test That specificity figure means some people who are not actually susceptible will still test positive, which has practical consequences: those false positives will be managed as susceptible for all future surgeries, an inconvenience but a safe one.
The test’s downsides are real. It requires a surgical biopsy, specialized laboratory equipment, and only a handful of centers worldwide can perform it. This is where genetic testing becomes increasingly relevant. Identified RYR1 mutations account for at least a quarter of known susceptible individuals in North America.13JAMA. Malignant Hyperthermia: Update on Susceptibility Testing If a family’s specific causative mutation is known, a blood test can screen other relatives without needing a muscle biopsy. The limitation is that a negative genetic test in someone whose family mutation is unknown does not rule out susceptibility, because the condition involves more than one gene and not all causative variants have been identified.
The Genetics Are More Complex Than One Gene
Most attention has focused on RYR1, but it is not the only gene implicated. Mutations in CACNA1S, which encodes a different calcium-related channel protein involved in the communication between a nerve signal and muscle contraction, are also recognized risk factors. However, the picture is complicated by genetic heterogeneity and incomplete penetrance, meaning the same mutation can produce different outcomes in different family members.14PubMed. Pharmacogenetics and pathophysiology of CACNA1S mutations in malignant hyperthermia At present, only a small number of CACNA1S variants have shown strong enough links to clinical episodes or positive contracture tests to be considered diagnostic.
The Clinical Pharmacogenetics Implementation Consortium has published guidelines for managing patients with known RYR1 or CACNA1S variants, recommending that carriers avoid all potent volatile anesthetics and succinylcholine.15PubMed Central. Clinical Pharmacogenetics Implementation Consortium (CPIC) Guideline for the Use of Potent Volatile Anesthetic Agents and Succinylcholine in the Context of RYR1 or CACNA1S Genotypes This pharmacogenetic approach represents a shift from reactive treatment to proactive avoidance: if you know your genotype, you can sidestep the trigger entirely.
Safe Anesthesia for Susceptible Patients
Susceptible patients absolutely can have surgery, and the anesthetic options available to them are safe and effective. Regional techniques like spinal anesthesia, epidural blocks, and peripheral nerve blocks are considered excellent choices because they avoid triggering agents altogether. When general anesthesia is needed, a trigger-free approach uses intravenous agents instead of inhaled gases. Propofol, for instance, has been shown to be safe both for induction and maintenance of anesthesia in susceptible patients. In laboratory testing, propofol did not cause abnormal contractions in susceptible human muscle and did not interfere with diagnostic biopsy results.16PubMed. Propofol is a ‘safe’ anaesthetic agent in malignant hyperthermia susceptible patients Non-depolarizing muscle relaxants, opioids, benzodiazepines, and nitrous oxide are also considered safe.17British Journal of Anaesthesia. European Malignant Hyperthermia Group guidelines for perioperative management of malignant hyperthermia-susceptible patients
An important but often overlooked step is preparing the anesthesia machine itself. Modern machines have internal components that absorb volatile anesthetic gases and slowly release them even when no fresh gas is being delivered. Simply turning off the vaporizer is not enough. Guidelines call for flushing the machine with high-flow oxygen for at least ten minutes to bring residual anesthetic levels below one part per million.18PubMed. Preparing a new generation anaesthetic machine for patients susceptible to malignant hyperthermia Some machine designs require much longer flush times; one widely used model needs at least 70 minutes of flushing at high flow to reach safe levels.19PubMed. Preparation of the Dräger Primus anesthetic machine for malignant hyperthermia-susceptible patients
To work around this, activated charcoal filters can be placed on the breathing circuit. These filters scrub residual gas quickly, bringing concentrations below the safety threshold within about ten minutes even on machines that would otherwise need lengthy flushing.20Anesthesia & Analgesia. Preparation of the Dräger Fabius Anesthesia Machine for the Malignant–Hyperthermia Susceptible Patient The charcoal filter must stay in place for the entire procedure. European guidelines list proper machine preparation as an obligatory step before anesthetizing a susceptible patient.21British Journal of Anaesthesia. European Malignant Hyperthermia Group guidelines for perioperative management of malignant hyperthermia-susceptible patients
Overlap With Central Core Disease and Other Myopathies
Because the RYR1 gene does more than just regulate the response to anesthetics, mutations in it can cause standalone muscle diseases as well. Central core disease is the best-known example. It is a congenital myopathy that typically shows up in infancy with low muscle tone, delayed motor milestones, and weakness concentrated around the hips. Central core disease and malignant hyperthermia susceptibility are considered allelic conditions, meaning they stem from mutations in the same gene and frequently co-occur in the same families.22PubMed Central. Central core disease Core myopathies in general carry a high risk of malignant hyperthermia susceptibility because of this genetic overlap.23PubMed. Core myopathies and malignant hyperthermia susceptibility: a review
RYR1 variants are actually the most common genetic cause of congenital myopathies broadly.24PubMed. Generation of two iPSC lines from patients with inherited central core disease and concurrent malignant hyperthermia caused by dominant missense variants in the RYR1 gene The practical implication is that anyone diagnosed with a RYR1-related myopathy should be treated as susceptible to malignant hyperthermia for anesthetic purposes, even if they have never had an episode. Their families should be evaluated as well.
The Link to Exertional Heat Stroke
Outside the operating room, there has been long-standing interest in whether malignant hyperthermia susceptibility makes people more vulnerable to exertional heat stroke during intense physical activity. The two conditions share several clinical features: dangerously elevated body temperature, muscle breakdown, metabolic crisis. Both involve skeletal muscle as the primary organ generating the problem. The hypothesis that they share underlying calcium-channel mechanisms is plausible but still debated. Some evidence supports the idea that mutations in calcium regulatory channels within skeletal muscle may mediate both conditions, but the relationship remains more suggestive than proven.25PubMed. Overlapping Mechanisms of Exertional Heat Stroke and Malignant Hyperthermia: Evidence vs. Conjecture
For susceptible individuals, the practical takeaway is that while the connection to exertional heat illness is not settled firmly enough to change exercise recommendations across the board, awareness matters. If you know you carry an RYR1 mutation, some caution during extreme heat and intense exertion is reasonable, and reporting any episodes of unexplained rhabdomyolysis or heat illness to your doctor is important for ongoing risk assessment.
What Families Should Know After an Episode
Malignant hyperthermia is inherited in an autosomal dominant pattern, meaning a single copy of a causative mutation from one parent is enough to confer susceptibility. Each child of a susceptible person has roughly a fifty-fifty chance of inheriting the variant. Because of this, guidelines recommend that survivors and their first-degree relatives be referred to a specialized malignant hyperthermia center for further testing and counseling.26PubMed. Updated guide for the management of malignant hyperthermia
In practice, many families do not follow through on this referral, and the condition can remain hidden for a generation until another family member encounters a triggering agent. A medical alert bracelet or card, consistent documentation in medical records, and proactive communication with any new surgical team are the most straightforward ways to protect yourself and your relatives. Most anesthesia departments have protocols in place for susceptible patients, but the system works best when the patient walks in already knowing their status.
Lessons From Pig Research
Pigs have been central to the understanding of malignant hyperthermia since the 1960s, when breeders noticed that certain lines of heavily muscled pigs would die suddenly under stress or during anesthesia. The porcine model led directly to the identification of RYR1 as the causative gene. More recent work has revealed that the picture in pigs is broader than originally appreciated. A study examining pigs that showed stress-syndrome symptoms under volatile anesthesia found that all affected animals tested negative for the known RYR1 mutation. Instead, a variant in the dystrophin gene was identified in a significant proportion of clinically affected animals. Body temperature increases under anesthesia were meaningfully larger in pigs carrying this dystrophin variant compared with noncarriers.27PubMed Central. The Incidence of Volatile Anesthesia Porcine Stress Syndrome in Pigs (Sus scrofa domesticus) Gives Implications for Physiology during Anesthesia
The researchers proposed an umbrella term, volatile anesthesia porcine stress syndrome, to encompass multiple genetic origins of anesthesia-related stress reactions in pigs, with classic RYR1-driven malignant hyperthermia being one subtype. Whether a similar broadening of genetic causes will be confirmed in humans remains to be seen, but the finding reinforces the lesson that genetic susceptibility to anesthetic crises may involve more pathways than the field currently tests for.